- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy, Cardiac Amyloidosis
- Interventions
- Not listed
- Lead sponsor
- eMyosound SAS
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
Condition Directory
Heart Failure clinical trials
Directory of U.S. ClinicalTrials.gov public records for Heart Failure. Browse Heart Failure recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 11, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
284
Shown on this page
12
Current sort
Recently updated
Condition scope
Heart Failure
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Heart Failure studies are organized in the registry
Heart failure records routinely distinguish reduced versus preserved ejection fraction — the abbreviations HFrEF and HFpEF appear directly in titles and condition fields and are the cleanest way to split the portfolio. Device and monitoring studies form a substantial share alongside drug trials.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 121–132 of 284 matching trials for Heart Failure.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases
- Interventions
- MANP, Sacubitril/Valsartan, Oral Placebo, Injection Placebo
- Drug
- Lead sponsor
- Horng Chen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- beta blocker discontinuation
- Other
- Lead sponsor
- UConn Health
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Normal Ejection Fraction, Heart Failure, Diastolic
- Interventions
- Exogenous Ketone Drink, Placebo
- Dietary Supplement
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Heart Failure
- Interventions
- Performance of WHEELS-I in promoting DASH/SRD adoption
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 45 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Customized Sleep Coaching, Sleep Hygiene Training
- Behavioral
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Heart Failure With Preserved Ejection Fraction, Pulmonary Hypertension
- Interventions
- HS135, Placebo
- Biological · Other
- Lead sponsor
- 35Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Kansas City, Missouri
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- AZD4831, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 21
- States / cities
- Alexander City, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more
- Conditions
- Heart Failure
- Interventions
- Finerenone (BAY94-8862), Placebo
- Drug · Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 6,016 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 98 more
- Conditions
- Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- Tirzepatide, Placebo
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 54
- States / cities
- Huntsville, Alabama • Beverly Hills, California • Covina, California + 51 more
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Atrial Flow Regulator, Sham Comparator
- Device
- Lead sponsor
- Occlutech International AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • New York, New York
- Conditions
- Type2diabetes, Heart Failure With Preserved Ejection Fraction
- Interventions
- Potato Starch
- Dietary Supplement
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
About this Heart Failure clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Heart Failure as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Heart Failure.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Heart Failure.